BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Figure out how to Perceive Warnings while Looking for an Auto Collision Lawyer - 25 VIP Voice Exhibitions in Energized Movies
- 310 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
- 435 million tons of food go to waste yearly in the US. Experts share tips to help stop it
- 55 Advancement Developments in Biotechnology
- IDF uncovers 7 km.-long Gaza terror tunnel where Hamas held Hadar Goldin
- Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
- Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- A definitive Manual for the Over-Ear Earphones
- Sydney Sweeney is returning in 'The Housemaid's Secret': What to know about 'The Housemaid' sequel
- Want to make America healthy again? Stop fueling climate change
- Rediscovering Euphoria: Individual Accounts of Conquering Despondency
- Carry Nature Inside with These Staggering Plant Decisions
